Rosiglitazone-Metformin Combination Versus Metformin-Sulfonylurea Combination On Beta-Cell Function In Type 2 Diabetes

• Status: Completed
• Trial end date: 2008-10-01
• Target enrollment: 0
• Participant gender: All

Summary

It has been shown in previous study that progressive glycemic deterioration was associated with progressive loss of b-cell function, measured by the decrease in plasma insulin levels, irrespective of the therapy used (diet, sulfonylureas or metformin).There is growing evidence that thiazolidinediones could have a positive action on the b-cell function. But it has not yet been demonstrated that they could protect from a deterioration in insulin secretion in the long term. So, it appears interesting to study the long term evolution of the b-cell function and the possible protection with rosiglitazone in patients with type 2 diabetes showing evidence of loss of b-cell function with metformin alone.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Gliclazide; Metformin; Rosiglitazone

Criteria

INCLUSION CRITERIA:

• Males and females 40 to 75 years of age (inclusive at the time of screening)

• Type 2 diabetes mellitus as defined by the WHO criteria, diagnosed for at least 1 year

• Subjects receiving 1.5 to 3g of metformin alone at a constant dose for at least 8 weeks prior to visit 1

• Patients with 6.5% < HbA1c > 8% at visit 1 and visit 2

• 25 < BMI < 35

EXCLUSION CRITERIA:

• Patient with type 1 diabetes

• Treatment with other hypoglycaemic agents than metformin in the last 3 months

• FPG >200 mg/dL at visit 2

• Hypersensitivity to the studied treatments (rosiglitazone, metformin chlorhydrate, gliclazide)

• Congestive heart failure (NYHA class I to IV), unstable or severe angina, recent myocardial infarction

• Respiratory insufficiency

• Subjects who have required the use of insulin for glycaemic control in the past 6 months prior to visit 1 (except during pregnancy or acute episodes such as hospitalization, trauma or infection) or subjects with a history of metabolic acidosis including diabetic ketoacidosis

• Anemia defined by haemoglobin concentration <11.0 g/dL for males and <10.0 g/dL for females

• Renal disease or renal dysfunction, e.g. as suggested by serum creatinine levels ≥135.0 µmol/L in males and ≥110.0 µmol/L in females and/or creatinine clearance <40 mL/min

• Presence of clinically significant hepatic disease, with ALT, AST, total bilirubin, alkaline phosphatase >2.5 times the upper limit of the normal reference range

• Subjects with chronic diseases requiring periodic ot intermittent treatment with oral or IV corticosteroids

• Subjects receiving danazol, miconazole or phenylbutazone

• Active alcohol, drug or medication abuse within the last 6 months or any condition that would indicate the likelihood of poor subject compliance

• Women who are lactating, pregnant or planning to become pregnant

• Any clinically significant abnormality identified at screening which, in the investigator's judgement, makes the subject unsuitable for inclusion in the study

• Use of any other investigational agent within 30 days or 5 half-lives (whichever is longer) prior to visit 1

• Subjects who receive or anticipate receiving radiocontrast dye during the study